Cargando…

Antithrombin Deficiency Is Associated with Prothrombotic Plasma Fibrin Clot Phenotype

Background  Deficiency of antithrombin increases risk of venous thromboembolism. We hypothesized that antithrombin deficiency affects fibrin clot structure and function. Methods  We evaluated 148 patients (age: 38 [32–50] years; 70% women) with genetically confirmed antithrombin deficiency and 50 he...

Descripción completa

Detalles Bibliográficos
Autores principales: Natorska, Joanna, Corral, Javier, de la Morena-Barrio, Maria Eugenia, Bravo-Pérez, Carlos, Bagoly, Zsuzsa, Bereczky, Zsuzsanna, Treliński, Jacek, Witkowski, Michał, Klajmon, Adrianna, Undas, Anetta, Ząbczyk, Michał
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460956/
https://www.ncbi.nlm.nih.gov/pubmed/37201530
http://dx.doi.org/10.1055/s-0043-1768712
_version_ 1785097750049718272
author Natorska, Joanna
Corral, Javier
de la Morena-Barrio, Maria Eugenia
Bravo-Pérez, Carlos
Bagoly, Zsuzsa
Bereczky, Zsuzsanna
Treliński, Jacek
Witkowski, Michał
Klajmon, Adrianna
Undas, Anetta
Ząbczyk, Michał
author_facet Natorska, Joanna
Corral, Javier
de la Morena-Barrio, Maria Eugenia
Bravo-Pérez, Carlos
Bagoly, Zsuzsa
Bereczky, Zsuzsanna
Treliński, Jacek
Witkowski, Michał
Klajmon, Adrianna
Undas, Anetta
Ząbczyk, Michał
author_sort Natorska, Joanna
collection PubMed
description Background  Deficiency of antithrombin increases risk of venous thromboembolism. We hypothesized that antithrombin deficiency affects fibrin clot structure and function. Methods  We evaluated 148 patients (age: 38 [32–50] years; 70% women) with genetically confirmed antithrombin deficiency and 50 healthy controls. Fibrin clot permeability (K (s) ) and clot lysis time (CLT) along with thrombin generation capacity were assessed before and after antithrombin activity normalization in vitro. Results  Antithrombin-deficient patients had lower antithrombin activity (−39%) and antigen levels (−23%) compared with controls (both p  < 0.01). Prothrombin fragment 1 + 2 levels were 26.5% higher in patients with antithrombin deficiency than in controls along with 94% increased endogenous thrombin potential (ETP) and 108% higher peak thrombin (all p  < 0.01). Antithrombin deficiency was associated with 18% reduced K (s) and 35% prolonged CLT (both p  < 0.001). Patients with type I ( n  = 65; 43.9%) compared with type II antithrombin deficiency ( n  = 83; 56.1%) had 22.5% lower antithrombin activity ( p  < 0.001) and despite similar fibrinogen levels, 8.4% reduced K (s) , 18% prolonged CLT, and 30% higher ETP (all p  < 0.01). Reduced K (s) was associated with lower antithrombin antigen level (β = − 6.1, 95% confidence interval [CI]: −1.7 to −10.5), while prolonged CLT was associated with lower antithrombin antigen (β = − 69.6, 95% CI: −9.6 to −129.7), activity (β = − 2.4, 95% CI: −0.3 to −4.5), higher PAI-1 (β = 12.1, 95% CI: 7.7–16.5), and thrombin-activatable fibrinolysis inhibitor levels (β = 3.8, 95% CI: 1.9–5.7). Addition of exogenous antithrombin reduced ETP (−42%) and peak thrombin (−21%), and improved K (s) (+8%) and CLT (−12%; all p  < 0.01). Conclusion  Our study suggests that enhanced thrombin generation and prothrombotic plasma fibrin clot phenotype can contribute to increased risk of thrombosis in patients with antithrombin deficiency.
format Online
Article
Text
id pubmed-10460956
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-104609562023-08-29 Antithrombin Deficiency Is Associated with Prothrombotic Plasma Fibrin Clot Phenotype Natorska, Joanna Corral, Javier de la Morena-Barrio, Maria Eugenia Bravo-Pérez, Carlos Bagoly, Zsuzsa Bereczky, Zsuzsanna Treliński, Jacek Witkowski, Michał Klajmon, Adrianna Undas, Anetta Ząbczyk, Michał Thromb Haemost Background  Deficiency of antithrombin increases risk of venous thromboembolism. We hypothesized that antithrombin deficiency affects fibrin clot structure and function. Methods  We evaluated 148 patients (age: 38 [32–50] years; 70% women) with genetically confirmed antithrombin deficiency and 50 healthy controls. Fibrin clot permeability (K (s) ) and clot lysis time (CLT) along with thrombin generation capacity were assessed before and after antithrombin activity normalization in vitro. Results  Antithrombin-deficient patients had lower antithrombin activity (−39%) and antigen levels (−23%) compared with controls (both p  < 0.01). Prothrombin fragment 1 + 2 levels were 26.5% higher in patients with antithrombin deficiency than in controls along with 94% increased endogenous thrombin potential (ETP) and 108% higher peak thrombin (all p  < 0.01). Antithrombin deficiency was associated with 18% reduced K (s) and 35% prolonged CLT (both p  < 0.001). Patients with type I ( n  = 65; 43.9%) compared with type II antithrombin deficiency ( n  = 83; 56.1%) had 22.5% lower antithrombin activity ( p  < 0.001) and despite similar fibrinogen levels, 8.4% reduced K (s) , 18% prolonged CLT, and 30% higher ETP (all p  < 0.01). Reduced K (s) was associated with lower antithrombin antigen level (β = − 6.1, 95% confidence interval [CI]: −1.7 to −10.5), while prolonged CLT was associated with lower antithrombin antigen (β = − 69.6, 95% CI: −9.6 to −129.7), activity (β = − 2.4, 95% CI: −0.3 to −4.5), higher PAI-1 (β = 12.1, 95% CI: 7.7–16.5), and thrombin-activatable fibrinolysis inhibitor levels (β = 3.8, 95% CI: 1.9–5.7). Addition of exogenous antithrombin reduced ETP (−42%) and peak thrombin (−21%), and improved K (s) (+8%) and CLT (−12%; all p  < 0.01). Conclusion  Our study suggests that enhanced thrombin generation and prothrombotic plasma fibrin clot phenotype can contribute to increased risk of thrombosis in patients with antithrombin deficiency. Georg Thieme Verlag KG 2023-05-18 /pmc/articles/PMC10460956/ /pubmed/37201530 http://dx.doi.org/10.1055/s-0043-1768712 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Natorska, Joanna
Corral, Javier
de la Morena-Barrio, Maria Eugenia
Bravo-Pérez, Carlos
Bagoly, Zsuzsa
Bereczky, Zsuzsanna
Treliński, Jacek
Witkowski, Michał
Klajmon, Adrianna
Undas, Anetta
Ząbczyk, Michał
Antithrombin Deficiency Is Associated with Prothrombotic Plasma Fibrin Clot Phenotype
title Antithrombin Deficiency Is Associated with Prothrombotic Plasma Fibrin Clot Phenotype
title_full Antithrombin Deficiency Is Associated with Prothrombotic Plasma Fibrin Clot Phenotype
title_fullStr Antithrombin Deficiency Is Associated with Prothrombotic Plasma Fibrin Clot Phenotype
title_full_unstemmed Antithrombin Deficiency Is Associated with Prothrombotic Plasma Fibrin Clot Phenotype
title_short Antithrombin Deficiency Is Associated with Prothrombotic Plasma Fibrin Clot Phenotype
title_sort antithrombin deficiency is associated with prothrombotic plasma fibrin clot phenotype
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460956/
https://www.ncbi.nlm.nih.gov/pubmed/37201530
http://dx.doi.org/10.1055/s-0043-1768712
work_keys_str_mv AT natorskajoanna antithrombindeficiencyisassociatedwithprothromboticplasmafibrinclotphenotype
AT corraljavier antithrombindeficiencyisassociatedwithprothromboticplasmafibrinclotphenotype
AT delamorenabarriomariaeugenia antithrombindeficiencyisassociatedwithprothromboticplasmafibrinclotphenotype
AT bravoperezcarlos antithrombindeficiencyisassociatedwithprothromboticplasmafibrinclotphenotype
AT bagolyzsuzsa antithrombindeficiencyisassociatedwithprothromboticplasmafibrinclotphenotype
AT bereczkyzsuzsanna antithrombindeficiencyisassociatedwithprothromboticplasmafibrinclotphenotype
AT trelinskijacek antithrombindeficiencyisassociatedwithprothromboticplasmafibrinclotphenotype
AT witkowskimichał antithrombindeficiencyisassociatedwithprothromboticplasmafibrinclotphenotype
AT klajmonadrianna antithrombindeficiencyisassociatedwithprothromboticplasmafibrinclotphenotype
AT undasanetta antithrombindeficiencyisassociatedwithprothromboticplasmafibrinclotphenotype
AT zabczykmichał antithrombindeficiencyisassociatedwithprothromboticplasmafibrinclotphenotype